CommercialCoverageLow impact
State and School Employees' Health Insurance Plan - Kebilidi (eladocagene exuparvovec-tneq)
Blue Cross & Blue Shield of Mississippi·MS · Neurology, Pediatrics, Internal Medicine·Medical Policy
Effective date
Sep 1, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has added a new policy classifying Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, as investigational and not covered. All services related to this medication will be considered not medically necessary without prior authorization approval.
Action Required
By September 1, 2025: Billing team must flag HCPCS code J3590 when used for Kebilidi (eladocagene exuparvovec-tneq) to ensure prior authorization is obtained through BCBSMS PA review process before treatment. Update billing system to alert staff that this gene therapy is considered investigational and claims will be denied without prior approval.